Captura

COVID-19 immunity in healthcare professionals

Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19 patients


Description of the Study:

  • Title: Immunitat en professionals sanitaris: cohort COVID CATCentral.
  • Principal investigators: Anna Ruiz Comellas, Anna Ramírez Morros, Josep Vidal Alball, Jacobo Mendioroz, Anna Forcada, Emma Cascant, Miquel Vázquez Santiago, Gemma Ruiz Olalla, Selena Alonso, Ruth Aguilar, Gemma Moncunill and Carlota Dobaño.
  • Centers of Implementation: Institut Català de la Salut and Institut de Salut Global de Barcelona (ISGlobal).
  • Study Population: Healthcare workers of Gerencia de la Catalunya Central (Bages, Berguedà, Anoia, Solsonès, Moianès and Osona) with clinic suggestive of COVID-19.
    – Inclusion criteria: Patients with clinical COVID-19 and at least one positive PCR or rapid antigen test will be included.
    – Exclusion criteria: Patients who do not agree to participate in the study.
  • Study Type: Prospective longitudinal cohort study.
  • Design: Prospective one-year longitudinal follow-up study of the COVID CATCentral cohort.
  • Methods: A total of 122 symptomatic primary health care professionals with positive PCR results for SARS-CoV-2 during the period of March 10 to April 10 will be studied. Clinical characteristics will be related to serological and cellular immunity results, collected in sequential monthly and bimonthly samples, respectively. Sequential plasma samples collected from 4 months to 16 months after symptom onset will be used.

Objectives of the Study:

Principal Objective: To characterize the SARS-CoV-2 antigen specific antibody profile and cellular immunity in blood samples collected prospectively for 12 months, by analyzing the kinetics, magnitude and durability in relation to the clinical presentation during the infection.

Secondary Objective: To describe the immunological factors associated with the different clinical manifestations of infection.

More about this Study:

Scientific Context: The immune response to SARS-CoV-2 virus with generation of antibodies (Ac) is observed, in most infected individuals, 10-15 days after the onset of COVID-19 symptoms. However, due to the recent emergence of this virus in the human population it is not yet known how long these Ac will be maintained or whether they will provide protection against reinfection.

Considering the possibility of a prolongation of the pandemic, the fact of having knowledge of immunity would translate into economic savings in diagnostic tests and in avoiding unnecessary isolations with the resulting socioeconomic impacts. It would also provide information at the pharmaceutical level in the treatment of serious patients and in the development of vaccines.

Icslogo
Baixa
Fundacio Daniel Bravo1

Other Studies about Serology:

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

CoViproteHCt

Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.

COVICAT Study

The COVICAT study aims to evaluate the evolution of the incidence of SARS-CoV-2 coronavirus infection in the Catalan population over a 12-month period.

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.

Covonco

COVonco Study

Join the COVonco study and help understand the impact of COVID-19 in oncology.

Fbdaf53c E60c 4f8c 9af5 Ce08e8ca65f0 4 5005 C

EpiCOV

The EpiCOV project aims to provide a global and scientifically reliable mapping of the immune status of the population in France through serological tests and questionnaires.

REACT-2.5: Seroprevalence of SARS-CoV-2 antibodies

This cross-sectional study estimates SARS-CoV-2 IgG antibody seroprevalence in the community in England using self-administered LFIAs.

Covid 5905183 1920

REACT-2.4: Usability of LFIA Self-testing in Key Workers

Study that assesses whether LFIAs should be used as a self-administered test among key workers or whether better performance is obtained if they attend a central clinic facility.

REACT-2.3: Acceptability and Usability of In-home Self-testing for SARS-CoV-2

This COVID-19 study aims to evaluate the acceptability and usability of in-home self-testing for SARS-CoV-2 antibodies.

Home Test 2

REACT-2.2: Feasibility of COVID-19 Self-testing

Which are the issues of self-testing? This study aims to assess the feasibility of finger-prick antibody testing at home to prove the design of the larger-scale COVID-19 studies.